Cardiology

Top Story

VIDEO: SCOT study addresses CV risk conferred by NSAIDs

August 31, 2015

LONDON — In this video, Richard A. Chazal, MD, FACC, medical director of the Heart and Vascular Institute at Lee Memorial Health System, Fort Myers, Florida, and president-elect of the American College of Cardiology, discusses results of the SCOT trial, which demonstrated low CV event rates in patients with arthritis but without known CVD assigned celecoxib or a nonselective nonsteroidal anti-inflammatory drug.

In the on-treatment population of the SCOT trial, presented by Thomas M. MacDonald, MD, FRCP, FESC, the rate of the primary outcome — hospitalization for nonfatal MI, nonfatal stroke or CV death — was 0.9 per 100 patient-years and 12 ulcer-related complications were reported, while there was no difference in the primary outcome between the two treatment groups.

Bryan Williams Meeting News CoveragePerspective

PATHWAY-2: Spironolactone benefits patients with resistant hypertension

August 31, 2015
LONDON — In patients with resistant hypertension despite guideline-directed medical therapy, the addition of spironolactone produced a greater reduction in BP than…
In the Journals

Diabetes, depression predict poor survival, rehospitalization in patients with heart failure

August 31, 2015
Poorer survival and rehospitalization in patients with heart failure are associated with comorbid diabetes and depressive symptoms, according to recent study findings…
In the Journals

Readmission rates may skew hospital quality measurements

August 31, 2015
Readmission rates were an ineffective measure of a hospital’s quality because they did not take into account readmissions from different hospitals, resulting in a…
Meeting News Coverage

ARTS-HF: Finerenone effective, safe in patients hospitalized for worsening HF

August 31, 2015
LONDON — In patients hospitalized for worsening HF, finerenone and eplerenone yielded similar decreases in the cardiac biomarker NT-proBNP at 90 days, but…
More News Headlines »
CME
PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor

PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »
Meeting News Coverage Video
VIDEO: ED protocol with high-sensitivity troponin assays helps rule out MI quickly

VIDEO: ED protocol with high-sensitivity troponin assays helps rule out MI quickly

August 30, 2015
LONDON — Joseph S. Alpert, MD, professor of medicine at the University of Arizona College of Medicine…
More »
CME
Spotlight on Hypercholesterolemia: New Ways to Test and Treat

Spotlight on Hypercholesterolemia: New Ways to Test and Treat

This activity is supported by an educational grant from Synageva BioPharma Corp.

Hereditary dyslipidemias are caused by single or multiple gene mutations that result in either overproduction or…
More »
morganatic-roan